Bioxeda — Competitive Intelligence Brief

Bioxeda (Eugenol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Standardized Chemical Allergen. Area: Cardiovascular.

marketed Standardized Chemical Allergen Arachidonate 5-lipoxygenase, Prostaglandin G/H synthase 1 Cardiovascular Small molecule

Target snapshot

Bioxeda (Eugenol) — HITEC-Institute of Medical Sciences. Bioxeda works by binding to and inhibiting the enzyme Prostaglandin G/H synthase 1, which plays a key role in the production of inflammatory mediators.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bioxeda TARGET	Eugenol	HITEC-Institute of Medical Sciences	marketed	Standardized Chemical Allergen	Arachidonate 5-lipoxygenase, Prostaglandin G/H synthase 1
TEPOXALIN	TEPOXALIN		marketed		Prostaglandin G/H synthase 2, Arachidonate 5-lipoxygenase, Prostaglandin G/H synthase 1
Inomax	NITRIC OXIDE	Vero Biotech Inc	marketed	Standardized Chemical Allergen [EPC]	Soluble guanylate cyclase	1999-01-01
Estrobene	DIETHYLSTILBESTROL	Tablicaps	marketed	Standardized Chemical Allergen [EPC]	Sodium/nucleoside cotransporter 1, 5-hydroxytryptamine receptor 6, Adenosine receptor A3	1973-01-01
Naphcon Forte	NAPHAZOLINE	Novartis	marketed	Non-Standardized Chemical Allergen [EPC]	Alpha-2A adrenergic receptor	1971-01-01
Infuvite Adult	Nicotinamide	Pfizer	marketed	Standardized Chemical Allergen [EPC]	NAD-dependent protein deacetylase sirtuin-2	1953-01-01
Cliquinol	CLIOQUINOL		marketed	Standardized Chemical Allergen [EPC]	Amyloid beta A4 protein	1934-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Standardized Chemical Allergen class)

1. · 7 drugs in this class
2. HITEC-Institute of Medical Sciences · 1 drug in this class